Interaction profile of moxifloxacin

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 235-236

  Stass, H ^a   Kubitza, D ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLDIGOXIN; CARDIAC GLYCOSIDE; MOXIFLOXACIN; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE; WARFARIN;

ADULT; AREA UNDER THE CURVE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

EID: 0032708157     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00073     Document Type: Conference Paper

References (6)

1. Stass H, Dalhoff A. Determination of BAY 12-8039, a new 8-methoxyquinolone, in human body fluids by high-performance liquid chromatography with fluorescence detection using on-column focusing. J Chromatogr 1997; 702: 163-74
2. Horstmann R, Delesen H, Dietrich D, et al. No drug-drug interaction between moxifloxacin and β-acetyldigoxin. J Clin Pharmacol 38: 879; 1998
3. Stass H, Müller F, Hundt HKL, et al. Study of the influence of once-daily 400 mg moxifloxacin on pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers [abstract no. A13]. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; Sep 24-28: San Diego. Washington, DC: American Society for Microbiology, 1998
4. Stass H, Kubitza D, Schwietert H, et al. BAY 12-8039 does not interact with theophylline. Proceedings of the 20th International Congress Chemotherapy; 1997 Jun 29-Jul 3: Sydney, Australia 1997: 3356, 108
5. Stass H, Dietrich H, Sachse E. Influence of a four-times dosing of 500 mg probenecid on kinetics of BAY 12-8039 after administration of a single 400 mg dose in healthy male volunteers [abstract no. F154]. Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1: Toronto, Canada. Washington, DC: American Society for Microbiology, 1997: 174
6. Stass H, Kubitza D. Moxifloxacin - review of clinical pharmacokinetics - absorption and bioavailability. Proceedings of the 6th International Symposium on New Quinolones and Related Antibiotics; 1998 Nov 15-17: Denver, USA, 1998: 8